Biomerieux SA (BIM) - Net Assets
Based on the latest financial reports, Biomerieux SA (BIM) has net assets worth €4.11 Billion EUR (≈ $4.80 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.57 Billion ≈ $6.52 Billion USD) and total liabilities (€1.47 Billion ≈ $1.72 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Biomerieux SA (BIM) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.11 Billion |
| % of Total Assets | 73.65% |
| Annual Growth Rate | 11.12% |
| 5-Year Change | 29.79% |
| 10-Year Change | 153.25% |
| Growth Volatility | 6.29 |
Biomerieux SA - Net Assets Trend (2005–2025)
This chart illustrates how Biomerieux SA's net assets have evolved over time, based on quarterly financial data. See BIM defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Biomerieux SA (2005–2025)
The table below shows the annual net assets of Biomerieux SA from 2005 to 2025. For live valuation and market cap data, see Biomerieux SA (BIM) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.11 Billion ≈ $4.80 Billion |
-2.49% |
| 2024-12-31 | €4.21 Billion ≈ $4.92 Billion |
+12.23% |
| 2023-12-31 | €3.75 Billion ≈ $4.39 Billion |
+3.00% |
| 2022-12-31 | €3.64 Billion ≈ $4.26 Billion |
+15.15% |
| 2021-12-31 | €3.16 Billion ≈ $3.70 Billion |
+27.50% |
| 2020-12-31 | €2.48 Billion ≈ $2.90 Billion |
+10.05% |
| 2019-12-31 | €2.25 Billion ≈ $2.64 Billion |
+12.62% |
| 2018-12-31 | €2.00 Billion ≈ $2.34 Billion |
+15.28% |
| 2017-12-31 | €1.74 Billion ≈ $2.03 Billion |
+7.12% |
| 2016-12-31 | €1.62 Billion ≈ $1.90 Billion |
+7.90% |
| 2015-12-31 | €1.50 Billion ≈ $1.76 Billion |
+8.20% |
| 2014-12-31 | €1.39 Billion ≈ $1.62 Billion |
+9.58% |
| 2013-12-31 | €1.27 Billion ≈ $1.48 Billion |
+5.59% |
| 2012-12-31 | €1.20 Billion ≈ $1.40 Billion |
+8.77% |
| 2011-12-31 | €1.10 Billion ≈ $1.29 Billion |
+13.04% |
| 2010-12-31 | €976.10 Million ≈ $1.14 Billion |
+21.04% |
| 2009-12-31 | €806.40 Million ≈ $942.77 Million |
+17.14% |
| 2008-12-31 | €688.40 Million ≈ $804.81 Million |
+14.49% |
| 2007-12-31 | €601.30 Million ≈ $702.98 Million |
+7.86% |
| 2006-12-31 | €557.50 Million ≈ $651.78 Million |
+11.84% |
| 2005-12-31 | €498.50 Million ≈ $582.80 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Biomerieux SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €397.50 Million | 9.69% |
| Common Stock | €12.00 Million | 0.29% |
| Other Components | €3.69 Billion | 90.02% |
| Total Equity | €4.10 Billion | 100.00% |
Biomerieux SA Competitors by Market Cap
The table below lists competitors of Biomerieux SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
$8.48 Billion |
|
Primerica Inc
NYSE:PRI
|
$8.48 Billion |
|
Orion Oyj B
HE:ORNBV
|
$8.48 Billion |
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
$8.48 Billion |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
$8.47 Billion |
|
Chang Hwa Commercial Bank Ltd
TW:2801
|
$8.47 Billion |
|
Hunan Yuneng New Energy Battery Material Co. Ltd. A
SHE:301358
|
$8.47 Billion |
|
Tongwei Co Ltd
SHG:600438
|
$8.47 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biomerieux SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,204,900,000 to 4,102,100,000, a change of -102,800,000 (-2.4%).
- Net income of 397,500,000 contributed positively to equity growth.
- Dividend payments of 106,100,000 reduced retained earnings.
- Share repurchases of 18,200,000 reduced equity.
- Other factors decreased equity by 376,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €397.50 Million | +9.69% |
| Dividends Paid | €106.10 Million | -2.59% |
| Share Repurchases | €18.20 Million | -0.44% |
| Other Changes | €-376.00 Million | -9.17% |
| Total Change | €- | -2.44% |
Book Value vs Market Value Analysis
This analysis compares Biomerieux SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.96x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.05x to 1.96x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €4.21 | €67.55 | x |
| 2006-12-31 | €4.71 | €67.55 | x |
| 2007-12-31 | €5.07 | €67.55 | x |
| 2008-12-31 | €5.78 | €67.55 | x |
| 2009-12-31 | €6.77 | €67.55 | x |
| 2010-12-31 | €8.21 | €67.55 | x |
| 2011-12-31 | €9.26 | €67.55 | x |
| 2012-12-31 | €10.09 | €67.55 | x |
| 2013-12-31 | €10.64 | €67.55 | x |
| 2014-12-31 | €11.67 | €67.55 | x |
| 2015-12-31 | €12.62 | €67.55 | x |
| 2016-12-31 | €13.68 | €67.55 | x |
| 2017-12-31 | €14.67 | €67.55 | x |
| 2018-12-31 | €16.28 | €67.55 | x |
| 2019-12-31 | €18.57 | €67.55 | x |
| 2020-12-31 | €20.49 | €67.55 | x |
| 2021-12-31 | €26.18 | €67.55 | x |
| 2022-12-31 | €30.43 | €67.55 | x |
| 2023-12-31 | €31.58 | €67.55 | x |
| 2024-12-31 | €35.41 | €67.55 | x |
| 2025-12-31 | €34.47 | €67.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biomerieux SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.69%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.77%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.36x
- Recent ROE (9.69%) is below the historical average (13.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 18.09% | 9.07% | 1.10x | 1.82x | €40.28 Million |
| 2006 | 18.90% | 10.16% | 1.10x | 1.69x | €49.59 Million |
| 2007 | 16.34% | 9.23% | 1.06x | 1.66x | €38.05 Million |
| 2008 | 18.99% | 11.71% | 0.93x | 1.74x | €61.53 Million |
| 2009 | 18.48% | 12.11% | 0.97x | 1.57x | €68.02 Million |
| 2010 | 16.47% | 11.79% | 0.94x | 1.49x | €62.83 Million |
| 2011 | 14.44% | 11.08% | 0.81x | 1.61x | €48.66 Million |
| 2012 | 11.26% | 8.56% | 0.86x | 1.54x | €15.06 Million |
| 2013 | 13.03% | 10.35% | 0.72x | 1.74x | €38.22 Million |
| 2014 | 9.77% | 7.94% | 0.66x | 1.87x | €-3.19 Million |
| 2015 | 7.39% | 5.62% | 0.71x | 1.86x | €-38.95 Million |
| 2016 | 11.06% | 8.52% | 0.69x | 1.87x | €17.19 Million |
| 2017 | 13.70% | 10.41% | 0.77x | 1.72x | €64.34 Million |
| 2018 | 13.31% | 10.60% | 0.69x | 1.82x | €63.80 Million |
| 2019 | 12.38% | 10.20% | 0.71x | 1.72x | €52.41 Million |
| 2020 | 16.63% | 12.97% | 0.79x | 1.62x | €161.29 Million |
| 2021 | 19.31% | 17.80% | 0.73x | 1.48x | €289.88 Million |
| 2022 | 12.55% | 12.60% | 0.69x | 1.44x | €91.98 Million |
| 2023 | 9.53% | 9.73% | 0.70x | 1.40x | €-17.62 Million |
| 2024 | 10.28% | 10.86% | 0.69x | 1.37x | €11.71 Million |
| 2025 | 9.69% | 9.77% | 0.73x | 1.36x | €-12.71 Million |
Industry Comparison
This section compares Biomerieux SA's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $689,812,225
- Average return on equity (ROE) among peers: 0.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biomerieux SA (BIM) | €4.11 Billion | 18.09% | 0.36x | $8.48 Billion |
| Eurofins-Cerep SA (ALECR) | $13.35 Million | -6.66% | 1.09x | $87.26 Million |
| Predilife (ALPRE) | $-12.10K | 0.00% | 0.00x | $11.09 Million |
| Eurofins Scientific SE (ERF) | $2.72 Billion | 8.23% | 1.65x | $10.22 Billion |
| Lumibird SA (LBIRD) | $23.73 Million | 0.00% | 1.92x | $489.86 Million |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more